## **AMENDMENTS TO THE CLAIMS**

This listing of claims will replace all prior versions, and listings, of claims in the application.

## **Listing of Claims:**

1-126. (Canceled)

- 127. (Currently amended) The antisense oligonucleotide of claim 125, An antisense oligonucleotide 20 to 30 nucleobases in length, or a salt form thereof, wherein the antisense oligonucleotide has a nucleobase sequence comprising the nucleobase sequence of SEQ ID NO:247.
- 128. (Currently amended) The antisense oligonucleotide of claim 127 125, wherein the antisense oligonucleotide is 20 nucleobases in length and has a nucleobase\_sequence consisting of the nucleobase sequence of SEQ ID NO:247.
- 129. (Currently amended) The antisense oligonucleotide of claim <u>127</u> <del>125</del>, wherein the antisense oligonucleotide comprises at least one modified internucleoside linkage.
- 130. (Previously presented) The antisense oligonucleotide of claim 129, wherein the modified internucleoside linkage is a phosphorothioate linkage.
- 131. (Currently amended) The antisense oligonucleotide of claim <u>127</u> <del>125</del>, wherein the antisense oligonucleotide comprises at least one modified sugar moiety.
- 132. (Previously presented) The antisense oligonucleotide of claim 131, wherein the modified sugar moiety is a 2'-O-methoxyethyl sugar moiety.
- 133. (Previously presented) The antisense oligonucleotide of claim 131, wherein the modified sugar moiety is a bicyclic sugar moiety.
- 134. (Currently amended) The antisense oligonucleotide of claim 127 125, wherein the antisense oligonucleotide is a chimeric oligonucleotide having a plurality of 2'-deoxynucleotides flanked on each side by at least one nucleotide having a modified sugar moiety.
- 135. (Previously presented) The antisense oligonucleotide of claim 134, wherein the modified sugar moiety is a 2'-O-methoxyethyl sugar moiety.
- 136. (Previously presented) The antisense oligonucleotide of claim 134, wherein the modified sugar moiety is a bicyclic sugar moiety.

2

- 137. (Currently amended) The antisense oligonucleotide of claim <u>127</u> <del>125</del>, wherein the antisense oligonucleotide comprises at least one modified nucleobase.
- 138. (Previously presented) The antisense oligonucleotide of claim 137, wherein the modified nucleobase is a 5-methylcytosine.
- 139. (Currently amended) The antisense oligonucleotide of claim 127 125, wherein the antisense oligonucleotide is a salt form.
- 140. (Previously presented) The antisense oligonucleotide of claim 139, wherein the salt form is a sodium salt form.
- 141. (Currently amended) A composition comprising the antisense oligonucleotide of any one of claims <del>125</del>-127 -140 and a pharmaceutically acceptable carrier or diluent.
- 142. (Previously presented) An antisense oligonucleotide 20 nucleotides in length having the sequence of nucleobases as set forth in SEQ ID NO:247 and comprising 5-methylcytosine at nucleobases 2, 3, 5, 9, 12, 15, 17, 19, and 20, wherein every internucleoside linkage is a phosphorothioate linkage, nucleotides 1-5 and 16-20 are 2'-O-methoxyethyl nucleotides, and nucleotides 6-15 are 2'-deoxynucleotides, or a salt thereof.
- 143. (Previously presented) The antisense oligonucleotide of claim 142, wherein the antisense oligonucleotide is a salt form.
- 144. (Previously presented) The antisense oligonucleotide of claim 143, wherein the salt form is a sodium salt form.
- 145. (Previously presented) A composition comprising the antisense oligonucleotide of any of claims 142 144 and a pharmaceutically acceptable carrier or diluent.

146-196. (Canceled)

- 197. (Previously presented) An antisense compound 12 to 30 nucleobases in length and fully complementary to SEQ ID NO:3, wherein said compound is targeted to the range of nucleotides 3230-3287 as set forth in SEQ ID NO:3, or a salt thereof.
- 198. (Previously presented) The antisense compound of claim 197, which is 12 to 20 nucleobases in length.
- 199. (Previously presented) The antisense compound of claim 197, which is an antisense oligonucleotide.
- 200. (Previously presented) The antisense oligonucleotide of claim 199, wherein the antisense oligonucleotide comprises at least one modified internucleoside linkage.

- 201. (Previously presented) The antisense oligonucleotide of claim 200, wherein the modified internucleoside linkage is a phosphorothioate linkage.
- 202. (Previously presented) The antisense oligonucleotide of claim 199, wherein the antisense oligonucleotide comprises at least one modified sugar moiety.
- 203. (Previously presented) The antisense oligonucleotide of claim 202, wherein the modified sugar moiety is a 2'-O-methoxyethyl sugar moiety.
- 204. (Previously presented) The antisense oligonucleotide of claim 202, wherein the modified sugar moiety is a bicyclic sugar moiety.
- 205. (Previously presented) The antisense oligonucleotide of claim 199, wherein the antisense oligonucleotide is a chimeric oligonucleotide having a plurality of 2'-deoxynucleotides flanked on each side by at least one nucleotide having a modified sugar moiety.
- 206. (Previously presented) The antisense oligonucleotide of claim 205, wherein the modified sugar moiety is a 2'-O-methoxyethyl sugar moiety.
- 207. (Previously presented) The antisense oligonucleotide of claim 205, wherein the modified sugar moiety is a bicyclic sugar moiety.
- 208. (Previously presented) The antisense oligonucleotide of claim 199, wherein the antisense oligonucleotide comprises at least one modified nucleobase.
- 209. (Previously presented) The antisense oligonucleotide of claim 208, wherein the modified nucleobase is a 5-methylcytosine.
- 210. (Previously presented) The antisense compound of claim 197, wherein the antisense compound is a salt form.
- 211. (Previously presented) The antisense compound of claim 210, wherein the salt form is a sodium salt form.
- 212. (Previously presented) A composition comprising the antisense compound of any one of claims 197-211 and a pharmaceutically acceptable carrier or diluent.
- 213.-215. (Canceled)
- 216. (Currently amended) <u>An antisense oligonucleotide 20 nucleobases in length</u> comprising at least 13 contiguous nucleobases of SEQ ID NO:247, or a salt form thereof. The antisense oligonucleotide of claim 125 which is 20 nucleobases in length.
- 217. (Previously presented) The antisense oligonucleotide of claim 216, having

- a gap segment of ten linked 2'-deoxynucleosides,
- a 5' wing segment of five linked nucleosides, and
- a 3' wing segment of five linked nucleosides,

wherein the gap segment is positioned between the 5' wing segment and the 3' wing segment, wherein each nucleoside of each wing segment comprises a 2'-O-methoxyethyl sugar modification, and wherein each internucleoside linkage is a phosphorothioate internucleoside linkage.

- 218. (Previously presented) The antisense oligonucleotide of claim 217, wherein the antisense oligonucleotide comprises at least one modified nucleobase.
- 219. (Currently amended) The antisense oligonucleotide of claim 218, comprising wherein the modified nucleobase is a 5-methylcytosine.
- 220. (Previously presented) The antisense oligonucleotide of claim 219, wherein each cytosine is a 5-methylcytosine.
- 221. (Currently amended) A composition comprising the antisense oligonucleotide of claim 125-127 and a penetration enhancer.
- 222. (Previously presented) The composition of claim 221, wherein the penetration enhancer is capric acid or lauric acid.
- 223. (Currently amended) A composition comprising the antisense oligonucleotide of claim 125-127 and at least one additional pharmaceutically active material.
- 224. (Currently amended) The composition of claim 223, wherein the at least one additional <u>pharmaceutically active material therapeutic agent</u> is an anti-inflammatory agent.
- 225. (Previously presented) The composition of claim 145, further comprising at least one additional pharmaceutically active material.
- 226. (Currently amended) The composition of claim 225, wherein the at least one additional <u>pharmaceutically active material therapeutic agent</u> is an anti-inflammatory agent.
- 227. (Previously presented) The antisense oligonucleotide of claim 197, which is 20 nucleobases in length.
- 228. (Previously presented) The antisense oligonucleotide of claim 227, having
  - a gap segment of ten linked 2'-deoxynucleosides, a 5' wing segment of five linked nucleosides, and
  - a 3' wing segment of five linked nucleosides,

5

wherein the gap segment is positioned between the 5' wing segment and the 3' wing segment, wherein each nucleoside of each wing segment comprises a 2'-O-methoxyethyl sugar modification, and wherein each internucleoside linkage is a phosphorothioate internucleoside linkage.

- 229. (Previously presented) The antisense oligonucleotide of claim 228, wherein the antisense oligonucleotide comprises at least one modified nucleobase.
- 230. (Previously presented) The antisense oligonucleotide of claim 229, comprising at least one modified cytosine, wherein the cytosine is a 5-methylcytosine.
- 231. (Previously presented) The antisense oligonucleotide of claim 230, wherein each cytosine is a 5-methyl cytosine.
- 232. (Previously presented) An oral formulation comprising the antisense compound of claim 197 and a pharmaceutically acceptable diluent or carrier.
- 233. (Previously presented) The formulation of claim 232, wherein said formulation comprises a penetration enhancer.
- 234. (Previously presented) The composition of claim 233, wherein the penetration enhancer is capric acid or lauric acid.
- 235. (Previously presented) A composition comprising the antisense oligonucleotide of claim 197 and at least one additional pharmaceutically active material.
- 236. (Currently amended) The composition of claim 235, wherein the at least one additional <u>pharmaceutically active material therapeutic agent</u> is an anti-inflammatory agent.
- 237. (Previously presented) The antisense oligonucleotide of claim 133, wherein the bicyclic sugar moiety has a (-CH<sub>2</sub>-)<sub>n</sub> group forming a bridge between the 2' oxygen ant the 4' carbon atoms of the sugar ring, wherein n is 1 or 2.
- 238. (Previously presented) The antisense oligonucleotide of claim 136, wherein the bicyclic sugar moiety has a (-CH<sub>2</sub>-)<sub>n</sub> group forming a bridge between the 2' oxygen ant the 4' carbon atoms of the sugar ring, wherein n is 1 or 2.
- 239. (Previously presented) The antisense oligonucleotide of claim 204 wherein the bicyclic sugar moiety has a (-CH<sub>2</sub>-)<sub>n</sub> group forming a bridge between the 2' oxygen ant the 4' carbon atoms of the sugar ring, wherein n is 1 or 2.

- 240. (Previously presented) The antisense oligonucleotide of claim 207 wherein the bicyclic sugar moiety has a (-CH<sub>2</sub>-)<sub>n</sub> group forming a bridge between the 2' oxygen ant the 4' carbon atoms of the sugar ring, wherein n is 1 or 2.
- 241. (New) The antisense oligonucleotide of claim 216, wherein the antisense oligonucleotide is fully complementary to SEQ ID NO:3.
- 242. (New) The antisense oligonucleotide of claim 127, having a gap segment of ten linked 2'-deoxynucleosides, a 5' wing segment of five linked nucleosides, and
  - a 3' wing segment of five linked nucleosides,

wherein the gap segment is positioned between the 5' wing segment and the 3' wing segment, wherein each nucleoside of each wing segment comprises a 2'-O-methoxyethyl sugar modification, and wherein each internucleoside linkage is a phosphorothioate internucleoside linkage.

- 243. (New) A composition comprising the antisense oligonucleotide of claim 142 and a penetration enhancer.
- 244. (New) The composition of claim 243, wherein the penetration enhancer is capric acid or lauric acid.
- 245. (New) A composition comprising the antisense oligonucleotide of claim 216 and a penetration enhancer.
- 246. (New) The composition of claim 245, wherein the penetration enhancer is capric acid or lauric acid.